| Literature DB >> 26626139 |
Yixin Niu1, Zhen Yang1, Xiaoyong Li1, Weiwei Zhang1, Shuai Lu2, Hongmei Zhang1, Xueru Chen1, Lingfei Zhu1, Yin Xing2, Guang Ning3,4, Li Qin5,6, Qing Su7.
Abstract
BACKGROUND: High osteoprotegerin (OPG) has been reported in association with insulin resistance and type 2 diabetes. We aimed to evaluate the association of serum OPG with impaired glucose regulation (IGR) and microalbuminuria among middle-aged and older Chinese.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26626139 PMCID: PMC4665817 DOI: 10.1186/s12902-015-0067-5
Source DB: PubMed Journal: BMC Endocr Disord ISSN: 1472-6823 Impact factor: 2.763
Characteristics of the study population
| Characteristic | NGR (0) | IGR | Type 2 diabetes (4) |
| Homogeneity of groups | ||
|---|---|---|---|---|---|---|---|
| Isolated IFG (1) | Isolated IGT (2) | IFG and IGT (3) | |||||
| n | 599 | 230 | 286 | 214 | 327 | - | - |
| Male, n(%) | 200 (43.4) | 96 (41.7) | 84 (29.4) | 86 (40.2) | 129 (39.4) | 0.008 | - |
| Age (years) | 54.2 ± 8.3 | 56.3 ± 7.5 | 55.6 ± 8.1 | 56.9 ± 7.4 | 57.3 ± 7.7 | <0.0001 | (0) (1,2,3,4) |
| BMI (kg/m2) | 24.4 ± 3.7 | 25.1 ± 3.4 | 24.7 ± 3.4 | 25.1 ± 3.9 | 25.5 ± 3.6 | <0.0001 | (0,1,2,3) (1,3,4) |
| Waist circumference (cm) | 84.0 ± 10.3 | 86.8 ± 10.0 | 84.5 ± 9.7 | 85.3 ± 11.8 | 88.0 ± 10.8 | <0.0001 | (0,2,3) (1.3) (1,4) |
| Waist/hip ratio | 0.88 ± 0.08 | 0.90 ± 0.09 | 0.89 ± 0.07 | 0.89 ± 0.13 | 0.93 ± 0.16 | 0.012 | (0,1,2,3) (1,2,3,4) |
| Fasting plasma glucose (mmol/l) | 5.5 ± 0.3 | 6.4 ± 0.2 | 5.6 ± 0.3 | 6.4 ± 0.2 | 7.5 ± 2.3 | <0.0001 | (0,2) (1,3) (4) |
| 2 h OGTT plasma glucose (mmol/l) | 6.1 ± 1.1 | 6.3 ± 1.0 | 9.0 ± 0.9 | 9.1 ± 0.9 | 13.2 ± 5.0 | <0.0001 | (0,1) (2,3) (4) |
| Fasting serum insulin (mmol/l) | 5.50 (3.90–7.63) | 6.20 (4.30–8.78) | 6.25 (4.23–8.60) | 6.80 (4.50–9.90) | 7.20 (4.70–10.20) | <0.0001 | (0) (1,2,3) (4) |
| Hemoglobin A1c (%) | 5.4 ± 0.3 | 5.6 ± 0.4 | 5.5 ± 0.3 | 5.7 ± 0.4 | 6.3 ± 1.4 | <0.0001 | (0) (1,2) (1,3) (4) |
| HOMA-IR | 1.39 (0.95–1.87) | 1.79 (1.26–2.53) | 1.64 (1.15–2.31) | 1.93 (1.33–2.80) | 2.37 (1.47–3.39) | <0.0001 | (0) (1,2) (1,3) (4) |
| Systolic blood pressure (mmHg) | 130 ± 19 | 136 ± 20 | 132 ± 19 | 139 ± 17 | 141 ± 20 | <0.0001 | (0,2) (1) (3,4) |
| Diastolic blood pressure (mmHg) | 81 ± 11 | 82 ± 10 | 82 ± 10 | 84 ± 11 | 84 ± 11 | <0.0001 | (0,1,2) (1,3) (3,4) |
| Total cholesterol (mmol/l) | 4.81 ± 0.83 | 5.09 ± 0.84 | 4.92 ± 0.86 | 5.13 ± 0.91 | 5.23 ± 0.91 | <0.0001 | (0,2) (1,3,4) |
| Triacylglycerol (mmol/l) | 1.39 ± 0.85 | 1.75 ± 1.36 | 1.83 ± 1.11 | 2.20 ± 1.85 | 2.17 ± 1.55 | <0.0001 | (0) (1,2) (3,4) |
| LDL-cholesterol (mmol/l) | 2.67 ± 0.70 | 2.83 ± 0.68 | 2.68 ± 0.68 | 2.81 ± 0.68 | 2.87 ± 0.77 | <0.0001 | (0,2) (1,3,4) |
| HDL-cholesterol (mmol/l) | 1.37 ± 0.30 | 1.34 ± 0.30 | 1.32 ± 0.29 | 1.28 ± 0.35 | 1.32 ± 0.33 | 0.009 | (0,1,2,4) (1,2,3,4) |
| White blood cell count (×109) | 5.7 ± 1.3 | 6.2 ± 1.5 | 6.2 ± 1.5 | 6.4 ± 1.6 | 6.5 ± 1.7 | <0.0001 | (0) (1,2,3) (3,4) |
| ACR (mg/g) | 7 (4–11) | 8 (5–14) | 8 (4–13) | 8 (5–15) | 10 (6–20) | <0.0001 | (0) (1,2,3) (4) |
| Serum creatinine concentration (mmol/l) | 62.0 (56.4–69.1) | 66.1 (60.4–74.3) | 62.5 (57.4–69.4) | 65.6 (59.4–73.0) | 66.3 (60.2–73.9) | 0.55 | (0,1,2,3,4) |
| GFR (ml min−1 1.73 m−2) | 126.7 (112.7–142.7) | 120.6 (108.4–136.3) | 122.7 (110.3–138.9) | 120.4 (106.8–133.8) | 118.5 (105.6–134.9) | 0.029 | (0,1,2,3) (4) |
| Current smoking, n (%) | 147 (24.5) | 56 (24.3) | 59 (20.6) | 65 (30.4) | 78 (23.9) | 0.172 | - |
| Alcohol intake, n (%) | 148 (24.7) | 68 (30.0) | 72 (25.2) | 72 (33.6) | 93 (28.4) | 0.099 | - |
| Postmenopausal women, n (%) | 301 (50.3) | 102 (44.3) | 153 (53.5) | 101 (47.2) | 156 (47.7) | 0.149 | - |
| OPG (μg/l) | 2.63 ± 0.95 | 2.95 ± 1.01 | 2.98 ± 1.03 | 2.96 ± 1.00 | 3.02 ± 1.09 | <0.0001 | (0) (1,2,3,4) |
Values are mean ± SD or median (interquartile range) or number (proportion)
p values were for the ANOVA or χ2 analyses across the five groups
Univariate and stepwise regression analysis with serum OPG concentration as a dependent variable
| Co-variable | Univariate | Stepwise | ||
|---|---|---|---|---|
| r |
| Beta |
| |
| Age (years) | 0.377 | <0.0001 | 0.331 | <0.0001 |
| Sex (male = 1, female = 2) | –0.12 | 0.440 | - | - |
| Body mass index (kg/m2) | 0.068 | 0.193 | - | - |
| Waist/hip ratio | 0.023 | 0.262 | - | - |
| Fasting plasma glucose (mmol/l) | 0.191 | 0.007 | - | - |
| 2 h OGTT plasma glucose (mmol/l) | 0.266 | <0.0001 | 0.222 | 0.002 |
| Log10 fasting serum insulin (mmol/l) | –0.125 | 0.056 | –0.175 | 0.021 |
| Hemoglobin A1c (%) | 0.251 | 0.001 | - | - |
| Log10 HOMA-IR | 0. 29 | <0.0001 | 0.20 | 0.003 |
| Systolic blood pressure (mmHg) | 0.104 | 0.092 | - | - |
| Diastolic blood pressure (mmHg) | 0.003 | 0.483 | - | - |
| Total cholesterol (mmol/l) | 0.113 | 0.075 | - | - |
| Triacylglycerol (mmol/l) | 0.222 | 0.002 | 0.255 | 0.001 |
| LDL-cholesterol (mmol/l) | 0.045 | 0.282 | - | - |
| HDL-cholesterol (mmol/l) | –0.057 | 0.235 | - | - |
| Log10 ACR | 0.09 | 0.05 | 0.16 | 0.025 |
| Blood cell count | 0.225 | <0.0001 | - | - |
Beta, Regression coefficient; r, Pearson correlation coefficient
Fig. 1Adjusted means (±SEM) of serum OPG concentrations in subjects with NGR, IGR (isolated IFG [Iso IFG], isolated IGT [Iso IGT] and IFG/IGT) and type 2 diabetes mellitus (T2DM). The covariables included age, sex, BMI, current smoking, current alcohol intake, menopausal status and the family history of diabetes. Subjects with type 2 diabetes mellitus and IGR (isolated IFG, isolated IGT and IFG/IGT) had higher concentrations of OPG than those with NGR (both p < 0.0001). There was no significant difference among the subgroups of IGR (p = 0.35) and between the IGR and type 2 diabetes mellitus groups (p = 0.61)
The risk of impaired glucose regulation and type 2 diabetes associated with a 0.1 μg/l increase in serum OPG
| Model | Adjustment | IGR (n = 730) |
| Impaired glucose regulation and type 2 diabetes ( |
|
|---|---|---|---|---|---|
| Model 1 | Unadjusted | 1.143 (1.112–1.174) | <0.0001 | 1.146 (1.127–1.167) | <0.0001 |
| Model 2 | Adjusted for age, gender, current smoking, current alcohol intake and family history of diabetes | 1.137 (1.108–1.166) | <0.0001 | 1.141 (1.115–1.168) | <0.0001 |
| Model 3 | Further adjusted for BMI and waist/hip ratio, based on Model 2 | 1.134 (1.104–1.165) | <0.0001 | 1.136 (1.107–1.166) | <0.0001 |
| Model 4 | Further adjusted for HOMA-IR, based on Model 3 | 1.133 (1.103–1.164) | <0.0001 | 1.132 (1.103–1.161) | <0.0001 |
| Model 5 | Further adjusted for serum triacylglycerol, total cholesterol, HDL- and LDL-cholesterol, based on Model 4 | 1.108 (1.009–1.117) | 0.01 | 1.121 (1.101–1.141) | 0.0005 |
Values are ORs (95 % CI)
aFor the risk of IGR, we defined participants with normal glucose regulation as 0 (n = 599) and IGR as 1 (n = 730), excluding patients with type 2 diabetes (n = 327) from the analysis
bFor the risk of combined IGR and type 2 diabetes, we defined participants with NGR as 0 (n = 599) and combined IGR and type 2 diabetes as 1 (n = 1,057)
Fig. 2Adjusted means (±SEM) of serum OPG concentrations in participants with normal urinary albumin excretion (Nor-AU) (n = 1,539), microalbuminuria (Micro-AU) (n = 103) and macroalbuminuria (Macro-AU) (n = 14). The co-variables included gender, age, BMI, waist circumference, waist/hip ratio, HOMA-IR, current smoking and alcohol intake, serum triacylglycerol, plasma glucose, blood pressure, menopausal status and use of antihypertensive drugs. There was no significant difference between the groups with micro- and macroalbuminuria (p = 0.69), while the OPG level was significantly higher in the group with microalbuminuria than in the normal group (p < 0.01)
The risk of micro- and macroalbuminuria associated with a 0.1 μg/l increase in serum OPG
| Model | Adjustment | Microalbuminuria ( |
| Micro- and macroalbuminuria ( |
|
|---|---|---|---|---|---|
| Model 1 | Unadjusted | 1.042 (1.026–1.058) | <0.0001 | 1.039 (1.022–1.056) | <0.0001 |
| Model 2 | Adjusted for sex, current smoking, current alcohol intake, ACEI/ARB use and family history of diabetes | 1.032 (1.017–1.046) | <0.0001 | 1.034 (1.019–1.050) | <0.0001 |
| Model 3 | Further adjusted for BMI and WHR, based on Model 2 | 1.027 (1.010–1.045) | 0.0007 | 1.029 (1.012–1.046) | <0.0001 |
| Model 4 | Further adjusted for HOMA-IR, based on Model 3 | 1.026 (1.010–1.042) | 0.0009 | 1.028 (1.012–1.044) | <0.0001 |
| Model 5 | Further adjusted for GFR, based on Model 4 | 1.29 (1.013–1.046) | 0.006 | 1.32 (1.018–1.046) | 0.0003 |
| Model 6 | Further adjusted for lipid profiles, based on Model 5 | 1.025 (1.006–1.044) | 0.02 | 1.026 (1.008–1.044) | 0.005 |
Values are ORs (95% CI)
aFor the risk of microalbuminuria, we defined participants with normal urinary albumin excretion as 0 (n=1,539) and microalbuminuria as 1 (n=103), excluding macroalbuminuria (n=14) from the logistic regression analyses
bFor the risk of combined micro- and macroalbuminuria, we defined participants with normal urinary albumin excretion as 0 (n=1,539) and combined micro- and macroalbuminuria as 1 (n=117)